Published in final edited form as:

Sex Transm Infect. 2018 June ; 94(4): 304–308. doi:10.1136/sextrans-2017-053334.

A cross-sectional study examining associations between substance use frequency, problematic use, and sexually transmitted infections among youth living with HIV

Kristi E. Gamarel¹, Sharon Nichols², Christopher W. Kahler³, Andrew O. Westfall⁴, Michelle A. Lally^{5,6}, and Craig M. Wilson⁷ the Adolescent Medicine Trials Network for HIV/AIDS Intervention

¹Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI USA

²Department of Medicine, University of California, San Diego, CA USA

³Center for Alcohol & Addiction Studies and Department of Behavioral and Social Science, Brown University School of Public Health, Providence, RI USA

⁴Department of Medicine, University of Alabama at Birmingham USA

⁵Lifespan Hospital System, Providence, RI USA

⁶Alpert Medical School, Brown University, Providence, RI USA

⁷Department of Epidemiology, University of Alabama at Birmingham, USA

Abstract

Objectives—This study sought to examine the prevalence of sexually transmitted infections (STIs) and whether substance use frequency and/or problematic use—specifically alcohol, marijuana, and other drugs—was associated with having an STI diagnosis among youth living with HIV (YLWH)

Methods—A sample of 823 YLWH were recruited at 14 adolescent HIV clinics through the Adolescent Medicine Trials Network for HIV Interventions. Study staff abstracted STI data from medical records for up to 26 weeks prior to participants' completing a cross-sectional survey including the ASSIST, which measures substance use frequency and consequences.

Corresponding Author: Kristi E. Gamarel, PhD, Department of Health Behavior and Health Education, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, Michigan 48109-2029, kgamarel@umich.edu.

Compliance with Ethical Standards:

Conflicts of Interest: Each of the authors declare that they have no conflict of interest

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The University of Alabama, Birmingham Institutional Review Board for Human Use approval number is X060303002.

Informed consent: Informed consent was obtained from all individual participants included in the study.

Contributions: K.E. Gamarel conceptualized the analysis, conducted all statistical analyses and wrote the first draft of the manuscript. MA Lally and CM Wilson conceptualized and oversaw the implementation of the initial study. S. Nichols, M.A. Lally, C.W. Kahler, and C.M. Wilson reviewed manuscript drafts and provided feedback. A.O. Westfall provided consultation on the analyses. All authors contributed to and have approved the final manuscript.

Results—Almost one-third of youth had been diagnosed with an STI (30.5%) at the time of their baseline assessment. In multivariable analyses, those who engaged in weekly or greater marijuana use (AOR=10.66, 95% CI: 4.39, 25.87, $p<0.001$) had an increased odds of being diagnosed with an STI. Additionally, youth who met alcohol use criteria for moderate (AOR = 5.23, 95% CI: 2.50, 10.93, $p<0.001$) and high risk (AOR = 6.53, 95% CI: 1.20, 35.68, $p<0.05$) alcohol use had an increased odds of being diagnosed with an STI compared with low risk alcohol users.

Conclusions—Study findings underscore the need to investigate the role of greater frequency of marijuana use and problematic alcohol use in STI incidence among YLWH. Given the associations between both substance use frequency and problematic use in STI diagnoses among youth living with HIV seen in HIV care settings, clinicians should use validated substance use screening tools which capture both frequencies and consequences in order to identify YLWH who may need further evaluation and treatment.

Introduction

Sexually transmitted infections (STIs) have the potential to amplify acquisition and infectiousness of HIV.¹ While accumulating evidence demonstrates that adherence to antiretroviral therapy (ART) nearly eliminates onward HIV transmission,^{2–5} some evidence suggests that the effectiveness of ART as an HIV prevention strategy may be lessened in the presence of an inflammatory STI.^{6–8} Thus, understanding the prevalence of and factors associated with STI incidence among youth living with HIV (YLWH) is an important public health concern to guide HIV prevention interventions and programs.

There is broad consensus that HIV transmission risk, including STI incidence, may be increased by substance use behaviors.^{9,10,11} Substance use, including marijuana, alcohol and other drug use, peaks in young adulthood and is especially high among young males.¹¹ Substance use, such as marijuana and alcohol use, have been shown to predict subsequent substance use problems, sexual risk behavior and STI acquisition in adolescent populations.^{12, 13} Alcohol and other substance use may impair young people's decision making and lower inhibitions, which may increase the likelihood of engaging in high risk sexual behaviors.¹⁴ Although studies suggest that alcohol, marijuana and other drug use are as prevalent among YLWH as in the general population,¹⁵ substance use may have more detrimental effects for YLWH.¹⁶ For example, evidence suggests that YLWH may experience structural and social vulnerabilities such as homelessness and incarceration, which may make them more vulnerable to engaging in substance use behaviors.¹⁶ To date, there is limited research examining whether greater frequencies of substance use behaviors or problematic use place YLWH at risk for STIs.

Given the recommendations for substance use screening in HIV care settings, there is a need for research to examine whether brief measures that solely capture frequency of substance use behaviors or screeners that assess problematic use are associated with STI diagnoses among YLWH to guide the implementation of screening and treatment. As such, the aim of the present study was to examine the relative associations between the frequency of alcohol, marijuana, and other drug use and indicators of problematic substance use in STI diagnoses to inform future research and programming.

Methods

Between February 2015 and February 2016, participants were recruited from 14 different adolescent medical clinics located throughout the United States to participate in a study. The details of the study have been published elsewhere.¹⁷ Adolescents were approached at one of their scheduled clinic visits by trained clinic research staff. To be eligible, youth had to be: 1) between 13 and 24 years of age; 2) living with HIV/AIDS; 3) aware that they were HIV-positive; 4) engaged in HIV care in one of the Adolescent Trial Network for HIV/AIDS Intervention (ATN) adolescent medicine clinical sites or affiliates; 5) behaviorally-infected with HIV; 6) able to understand written and/or spoken English; and 7) have medical records that could be accessed by research staff. The study was approved by the Institutional Review Boards (IRB) at each participating site and protocol team members.

After the initial screening process, informed consent or youth assent was obtained from those who agreed to participate. There were two sites that did not allow waiver of parental permission for those under age 18 for this study. Therefore, at these two sites for those under the age 18, youth provided assent and parental permission was required. All of the other sites allowed a waiver of parental permission and youth provided informed consent. In total, 1038 youth were approached to participate in the study. Of these youth, 73 declined to participate, 17 could not be contacted, and an additional 24 youth were in various stages of recruitment when the study was closed. Additionally, 101 youth were enrolled in the study but had less than 6 months of follow-up STI data when the study was closed. Thus, the final analytic sample consisted of 823 youth who were eligible and participated in the study, which included completing a one-time audio-computer assisted self-interview (ACASI) that included multiple psychosocial and behavioral measures and had at least 6 months of follow-up medical chart abstract data. Participants received an incentive with amount determined by each site's IRB for their time and effort completing the assessment. Research staff then abstracted STI diagnoses from each participant's medical record for the 26 weeks prior to their enrollment and ACASI date. STI information in the medical chart included laboratory notes, verbal report by a clinician or verbal report by the participant.

Measures

Sociodemographic variables—Participants self-reported their age, race/ethnicity, past history of incarceration, and living situation. Participants were also asked their sex assigned at birth (male vs. female), gender identity (male, female, or transgender). Transgender participants were coded as those who reported a sex assigned at birth that did not match their gender identity or those who identified their gender identity as transgender. Based on this classification, there were three groups of participants: 1) cisgender male, 2) cisgender female, and 3) transgender women. There were no transgender men in this sample.

Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)—

Participants completed the ASSIST to assess alcohol, marijuana, and other drug use. The ASSIST developed as a substance use screening tool for individuals 18 and above and has been used in several studies of YLWH ages 15 to 24 years of age.^{18–22} The ASSIST includes frequency of use in the prior 3 months for alcohol, cannabis, cocaine, amphetamines,

inhalants, sedatives, hallucinogens, opioids, and other drugs, with frequency categories of “Never”, “Once or Twice”, “Monthly”, “Weekly”, and “Daily.” Consistent with other studies of YLWH and the distribution of the frequencies,¹⁶ we created three indicators of substance use behavior, which included: 1) alcohol use (1=daily/almost daily or weekly versus 0=one or more times per month or never); 2) marijuana use (1=daily/almost daily or weekly versus 0=one or more times per month or never); and 3) endorsement of any past three-month other drug use (i.e., crack, cocaine, amphetamine, inhalants, opioids, sedatives, hallucinogens; 1=yes versus 0=no) because of the few participants who reported any weekly or more other drug use (i.e., 2.8%, n=23 endorsed weekly use and 1.2%, n=10) reported daily or almost daily use). The ASSIST also comprises of seven questions for each drug category, and an additional question on injecting any drug. It identifies the substances used, frequency of use and substance-related harm over the past 3 months (e.g., “has use led to health, social, legal or financial problems?”; “Has a friend or relative or anyone else ever expressed concern about your use?”). Using the ASSIST manual scoring guidelines, we created a risk score by summing 3-month frequency and harm items for each substance, which we then categorized as low-, moderate- or high-risk. Marijuana risk scores were calculated as low risk (0–3), moderate risk (4–26), and high risk (27 or higher), and alcohol risk scores were calculated as low risk (0–10), moderate risk (11–26) and high risk (27 or higher). Given the small number of participants who reported other drug use, we created a series of moderate and high risk variables for each non-marijuana drug use and then created a single dichotomous moderate and high risk variable for any participants who met criteria for moderate (11–26) and high risk (27 or higher) based on any non-marijuana drugs.

Sexually Transmitted Infections (STIs)—As described above, research staff abstracted information from each participant’s medical record regarding any diagnosis of Chlamydia, Gonorrhea, and Syphilis. The majority of STI results were based on laboratory reports (91.7%), with 10.1% based on clinician notes and less than 1% based on a verbal report from the participant. We created a dichotomous variable of any STI diagnosis (1=Yes vs. 0=No).

Statistical Analyses

First, we examined descriptive statistics for sociodemographic, substance use, and STI variables. Second, we conducted bivariate analyses to examine whether there were differences in sociodemographic and substance use variables by STI diagnosis using independent *t*-tests for continuous variables and chi-square tests for categorical variables. In the case where there was sparse data (i.e., cell sizes were <5), we utilized Fisher’s exact tests to obtain exact *p*-values; however, we still report findings from the chi-square test statistics. Finally, we fit a multivariable generalized estimating equation (GEE) model to examine associations between substance use risk, substance use behaviors, sociodemographic variables, and STI diagnoses while accounting for the multi-site nature of the study design. GEE models obtain more accurate estimates by treating dependency between participants within study site as a nuisance parameter and provide more precise estimates by statistically adjusting for this dependency.²² All analyses were conducted in SPSS 24 with a specified *p*-value of 0.05.

Results

Sample Characteristics

Table 1 presents the characteristics of the study sample by STI diagnosis. Almost one-third of youth had been diagnosed with an STI (30.5%) 26 weeks prior to the baseline visit. Participants ranged in age from 16 to 24 (Mean=21.48, SD = 2.01). The majority of the sample were members of racial/ethnic minority groups and self-reported a male gender identity. With regards to socio-structural factors, nearly one in ten participants reported unstable housing or homelessness and over one-third of the sample reported a history of criminal justice involvement. The majority of the sample reported at least monthly or greater alcohol use and over one-quarter of the sample met criteria for moderate to high risk alcohol use. Nearly one-third of the sample reported daily or almost daily marijuana use, with almost an additional third reporting monthly or greater marijuana use. Over half of the sample met criteria for moderate or high risk marijuana use. Approximately one-quarter of participants reported any other drug use in the past 3 months.

As shown in Table 1, a greater proportion of males were diagnosed with an STI compared to female participants. A higher proportion of participants who met criteria for high risk alcohol use and marijuana use were diagnosed with an STI compared to those who were low risk. Those who reported daily/almost daily and weekly marijuana use were more likely to be diagnosed with STI compared to those who reported no marijuana use. Similarly, youth who reported using other drugs and were younger in age were significantly more likely to be diagnosed with STI.

Table 2 presents the multivariable model examining whether the frequency of substance use behaviors or substance use risk were associated with being diagnosed with STI over 26 weeks. Males compared to females had an increased odds of being diagnosed with an STI (AOR = 6.50, 95% CI: 2.97, 14.22, $p<0.001$). Youth who reported weekly or greater marijuana use (AOR=10.66, 95% CI: 4.39, 25.87, $p<0.001$) compared to those who reported monthly or no marijuana had an increased odds of being diagnosed with an STI compared to no drug use. Additionally, youth who met criteria for moderate (AOR = 5.23, 95% CI: 2.50, 10.93, $p<0.001$) and high risk (AOR = 6.53, 95% CI: 1.20, 35.68, $p<0.05$) alcohol use had an increased odds of being diagnosed with an STI compared with low risk alcohol users.

Discussion

In this sample of YLWH, we found a high incidence of STI diagnoses with estimates similar to those found in samples of adults living with HIV.²¹ Routine STI screening has been recommended for all sexually-active individuals, including adolescents,^{18,21,25} and has been implemented in many HIV clinics in the United States. Consistent with prior studies,¹⁶ study findings underscore the necessity of routine STI screening and testing in primary care setting for YLWH, particularly for youth who use psychoactive substances.

After adjusting for sociodemographic factors and study site, both substance use frequency and problematic use remained a significant predictor of being diagnosed with an STI. More frequent use of marijuana (weekly or greater) was associated with higher likelihood of STI

in the past six months. Notably, youth who met criteria for moderate and high risk alcohol use had an increased odds of STI period prevalence. Given that some level of alcohol use is common in this age group and in our sample, indications of adverse consequences from alcohol use as assessed by the ASSIST may be a better indicator of risk for STIs than use itself. Since screening for problematic alcohol use is recommended for primary care, reports of adverse consequences in this population should raise suspicion for STIs and serve as an additional indicator for STI screening.

Substance use, specifically marijuana use typically emerges in adolescence and progresses into young adults,²⁶ and studies have found that youth initiate marijuana use to cope with stressors, including living with limited resources.²⁷ Consistent with prior research with YLWH, we found that daily/almost daily marijuana use was highly prevalent in this sample.²⁷ Although there may be overlap in youth who use marijuana for recreational versus medicinal purposes, research has also shown that marijuana use plays a role in symptom and stress management among YLWH.²⁸ Given the associations between daily chronic marijuana use and pulmonary disease²⁹ and cognitive dysfunction³⁰ in adult populations, these findings corroborate recent calls for further study into the longer-term effects of marijuana use on YLWH^{27,28} and highlight the necessity of assessing frequency and indicators of problematic use in clinical settings.

Limitations

Study findings must be interpreted within the context of their limitations. Although ACASI technology was used to reduce social desirability bias, substance use data was based on self-report and there may be social desirability and recall bias. However, previous studies have found strong associations between self-report and substance use.²¹ We were only able to collect substance use information at one time point, which limits our ability to determine whether substance use is causally related to STI diagnoses. The time frame for reporting substance use was within the past 3 months and does not completely cover the entirety of STI medical record abstraction. While the sociodemographic characteristics of the sample are similar to other national samples of YLWH, this is a sample of youth who knew their HIV status and were engaged in HIV care, which limits generalizability to youth who may not know their HIV status or be linked to HIV care services. Although the ASSIST has been used in studies with YLWH to identify problematic use,^{17–21} the cutoff scores for problematic use were developed and validated with individuals 18 years of age and older. Thus, future research is warranted to provide validation for the cutoff scores for youth under the age of 18. Additionally, we did not collect self-report sexual orientation identity data, which limits our ability to determine whether these findings may be stronger among young gay, bisexual, and other men who have sex with men compared to cisgender women and their cisgender male heterosexual counterparts.

Conclusions

Despite the study limitations, this study provides new information into the relationships between substance use risk, frequency behaviors, and STI incidence among YLWH. Given the complex associations between substance use and STI diagnoses among YLWH seen in

HIV care settings, clinicians should utilize validated screening tools which capture both frequency and potential risk and implement brief interventions for problematic substance use to recognize YLWH who may be in need of further treatment. Furthermore, these findings underscore the importance of additional research on the effects of marijuana use among YLWH to develop appropriate interventions for reducing STI incidence and HIV transmission.

Acknowledgments

Clinics were located in the following locations: Los Angeles, California; Washington, DC; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Philadelphia, Pennsylvania; New York City, New York; New Orleans, Louisiana; Memphis, Tennessee; Miami, Florida; Tampa, Florida; Detroit, Michigan; Denver, Colorado; and Houston, Texas.

This research was supported by The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) from the National Institutes of Health [U01HD040533 and U01HD040474] through the National Institute of Child Health and Human Development (Kapogiannis, Lee), with supplemental funding from the National Institutes on Drug Abuse (Davenny, Kahana) and Mental Health (Brouwers, Allison). Support was also provided to the first and fifth author by the Providence/Boston Center for AIDS Research (P30AI042853, PI: Cu-Uvin). The study was scientifically reviewed by the ATN's Behavioral Leadership Group. Network, scientific and logistical support was provided by the ATN Coordinating Center (Wilson, Partlow) at the University of Alabama at Birmingham. Network operations and data management support was provided by the ATN Data and Operations center at Westat, Inc. (Korelitz, Driver).

We acknowledge the contribution of the investigators and staff at the following sites that participated in this study: University of South Florida, Tampa (Emmanuel, Lujan-Zilbermann, Julian), Children's Hospital of Los Angeles (Belzer, Flores, Tucker), Children's National Medical Center (D'Angelo, Hagler, Trexler), Children's Hospital of Philadelphia (Douglas, Tanney, DiBenedetto), John H. Stroger Jr. Hospital of Cook County and the Ruth M. Rothstein CORE Center (Martinez, Bojan, Jackson), Montefiore Medical Center (Futterman, Enriquez-Bruce, Campos), Tulane University Health Sciences Center (Abdalian, Kozina, Baker), University of Miami School of Medicine (Friedman, Maturo, Major-Wilson), St. Jude's Children's Research Hospital (Flynn, Dillard), Baylor College of Medicine (Paul, Calles, Cooper), Wayne State University (Secord, Cromer, Green-Jones), Johns Hopkins University School of Medicine (Agwu, Anderson, Park), The Fenway Institute – Boston (Mayer, George, Dormitzer), and University of Colorado, Denver (Reirden, Hahn, Witte). We are greatly appreciative to all of the adolescents and young adults who participated in this study.

References

1. Johnson LF, Lewish DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: A systematic review and meta-analysis. *Sex Transm Dis.* 2008; 35:946–959. [PubMed: 18685546]
2. Grant RM, Lama JR, Anderson PL. Preexposure chemoprophylaxis for HIV infection in men who have sex with men. *N Eng J Med.* 2010; 363:2587–2599.
3. Baetan D, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV protection in heterosexual men and women. *N Eng J Med.* 2012; 367:399–410.
4. Das EM, Chu PL, Santos GM. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. *PLoS One.* 2010; 5:e11068. [PubMed: 20548786]
5. Rodger, Alison J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. *JAMA.* 2016; 316:171–181. [PubMed: 27404185]
6. Lambert-Niclot S, Tubiana R, Beaudox C, et al. Detection of HIV-1 RNA in seminal plasma samples of treated patients with undetectable HIV-1 RNA in blood samples on a 2002–2011 survey. *AIDS.* 2012; 26:971–975. [PubMed: 22382146]
7. Fisher M, Pao D, Brown AE, Sudarshi D, Gill OE, et al. Determinants of HIV-1 transmission in men who have sex with men: A combined clinical, epidemiological, and phylogenetic approach. *AIDS.* 2010; 24:1739–1747. [PubMed: 20588173]

8. Politch JA, Mayer KH, Welles SL, O'Brien WX, Xu C, Bowan DJ. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. *AIDS*. 2012; 26:1535–1543. [PubMed: 22441253]
9. Purcell DW, Parsons JT, Halkitis PN, Mizuno Y, Woods WJ. Substance use and sexual transmission risk behavior of HIV-positive men who have sex with men. *J Subs Abuse*. 2001; 13(1–2):185–200.
10. Elkington KS, Bauermeister JA, Robbins RN, et al. Individual and contextual factors of sexual risk behavior in youth perinatally infected with HIV. *AIDS Patient Care STDs*. 2012; 26(7):411–422. [PubMed: 22694193]
11. Tapert SF, Aarons GA, Sedlar GR, Brown SA. Adolescent substance use and sexual risk-taking behavior. *J Adolesc Health*. 2001; 28(3):181–189. [PubMed: 11226840]
12. Seth P, Wingood GM, DiClemente RJ, Robinson LS. Alcohol use as a marker for risky sexual behaviors and biologically confirmed sexually transmitted infections among you adult African American women. *Women's Health Issues*. 2011; 21(2):130–135. [PubMed: 21276736]
13. Khan MR, Berger AT, Wells BE, Cleland CM. Longitudinal associations between adolescent alcohol use and adulthood sexual riisk behavior and sexually transmitted infections in the United States: Assessment of difference by race. *Am J Public Health*. 2012; 102(5):867–876. [PubMed: 22493999]
14. Mustanski B, Byck GR, Newcomb ME, Henry D, Bolland J, Dick D. HIV information and behavioral skills moderate the effects of relationship type and substance use on HIV risk behaviors among African American youth. *AIDS Patient Care STDs*. 2013; 27(6):342–351. [PubMed: 23701198]
15. National Institute on Drug Abuse. Drug abuse and addiction: one of America's most challenging public health problems. 2005
16. Gamarel KE, Brown L, Kahler CW, et al. Prevalence and correlates of substance use among youth living with HIV in clinicall settings. *Drug Alc Depend*. 2016; 1(169):11–18.
17. Lally MA, Van den Berg JV, Westfall AO, Ruby BJ, Hosek S, Fortenberry JD, Monte D, Tanney M, McFarland E, Xu J, Kapogiannis B, Wilson CM. HIV Continuum of Care for Youth in the United States. *J Aquir Immun Defic Syndr*. in press.
18. World Health Organization. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. *Addiction*. 2002; 97:1183–1194. [PubMed: 12199834]
19. Naar-King S, Holmodin K, Parsons JT, Murphey D. ATN 004 Protocol Team. Psychosocial factors and substance use in high-risk youth living with HIV: A multi-site study. *AIDS Care*. 2010; 22(4): 457–482.
20. Gamarel KE, Nelson KM, Brown L, Fernandez MI, Nichols S. The usefulness of the CRAFFT in screening youth for problematic drug and alcohol use among youth living with HIV. *AIDS Behav*. 2016
21. Nichols SL, Lowe A, Zhang X, et al. Concordance between self-reported substance use and toxicology among HIV-infected and uninfected at risk youth. *Drug Alc Depend*. 2014; 134:376–382.
22. Burton P, Gurrin L, Sly P. Tutorial in biostatistics: Extending the simple linear regression model to account for correlated responses: An introduction to generalized estimating equations and multi-level mixed modeling. *Statistics Med*. 1998; 17:1261–1291.
23. Mulhall BP, Wright S, Allen D, et al. High rates of sexually transmittible infections in HIV-positive patients in the Australian HIV Observational Database: A prospective cohort study. *Sexual Health*. 2014; 11:291–297. [PubMed: 25109880]
24. Centers for Disease Control and Prevention. Sexually Transmitted Diseases. 2017
25. Merikangas KR, J-p H, Burstein M, et al. Lifetime prevalence of mental disorders in US adolescents: Results from the National Comorbidity Survey Replication-Adolescent Supplement (NCSA). *J Am Acad Child Adolesc Psychiatry*. 2010; 49(10):980–989. [PubMed: 20855043]
26. Nation M, Heflinger CA. Risk factors for serious alcohol and drug use: the role of psychosocial variables in predicting the frequency of substance use among adolescents. *Am J of Alcohol Abus*. 2006; 32(3):415–433.

27. Bruce D, Kahana SY, Bauermeister JA, et al. Neighborhood-level and individual correlates of cannabis use among young persons living with HIV/AIDS. *Drug Alc Depend.* 2015; 151:173–180.
28. Bruce D, Harper GW, Fernández MI. the Adolescent Medicine Trials Network for HIV AIDS Interventions. Heavy marijuana use among gay and bisexual male emerging adults living with HIV/AIDS. *J HIV/AIDS Soc Serv.* 2013; 12:66–88.
29. Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. *New Engl J Med.* 1988; 318:347–351. [PubMed: 3340105]
30. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. *JAMA.* 2002; 287:1123–1131. [PubMed: 11879109]

Key Points

- Nearly one-third of youth living with HIV were diagnosed with chlamydia, gonorrhea, or syphilis over the 26 week period prior to completing a cross-sectional survey.
- Marijuana, alcohol use and other drug use were each independently and significantly associated with having an STI diagnosis.
- Findings underscore the importance of routine STI and substance use screening and treatment in HIV care.

Table 1

Sample Characteristics by STI Diagnosis (N = 823)

	STI Diagnosis^c			Test Statistic
	Total N=823	Yes (n=251, 30.5%)	No (n=572, 69.5%)	
	N (%)	N (%)	N (%)	
<i>Gender Identity</i>				$\chi^2(2)=21.17, p<0.001$
Female	155 (18.8)	24 (15.5)	131 (84.5)	
Male	641 (77.9)	220 (34.3)	421 (65.7)	
Transgender	27 (3.3)	7 (25.9)	20 (74.1)	
<i>Race/Ethnicity</i>				$p=0.708$
White, non-Hispanic	30 (3.6)	8 (26.7)	22 (73.3)	
Black, non-Hispanic	601 (73.0)	186 (30.9)	415 (69.1)	
Hispanic/Latino	149 (18.1)	43 (28.9)	106 (71.1)	
Other, non-Hispanic	40 (4.9)	14 (35.0)	26 (65.0)	
<i>Current Unstable Housing</i>				$p=0.419$
Yes	72 (8.8)	25 (34.7)	47 (65.3)	
No	750 (91.2)	226 (30.1)	524 (69.9)	
<i>Incarceration, lifetime</i>				$p=0.591$
Never	498 (60.7)	152 (30.5)	346 (69.5)	
1 time	156 (19.0)	53 (34.0)	103 (66.0)	
2 to 5 times	125 (15.2)	33 (26.4)	92 (73.6)	
6 or more times	41 (5.0)	12 (29.3)	29 (70.7)	
<i>Alcohol Use, past 3 months</i>				$p=0.137$
Daily/Almost Daily	33 (4.0)	12 (36.4)	21 (63.6)	
Weekly	169 (20.6)	55 (32.5)	114 (67.5)	
Monthly	461 (56.2)	147 (31.9)	314 (68.1)	
Never	157 (19.1)	36 (22.9)	121 (77.1)	
<i>Alcohol Risk Score</i>				$\chi^2(2)=8.60, p=0.014$
Low Risk	594 (72.4)	164 (27.6)	430 (72.4)	
Moderate Risk	197 (24.0)	74 (37.6)	123 (62.4)	
High Risk	29 (3.5)	12 (41.4)	17 (58.6)	
<i>Marijuana Use, past 3 months</i>				$\chi^2(3)=17.12, p=0.001$
Daily/Almost Daily	257 (31.5)	98 (38.1)	159 (61.9)	
Weekly	80 (9.8)	31 (38.8)	49 (61.3)	
Monthly	168 (20.6)	48 (28.6)	120 (71.4)	
Never	311 (38.1)	73 (23.5)	238 (76.5)	
<i>Marijuana Risk Score</i>				$\chi^2(2)=18.04, p<0.001$
Low Risk	327 (40.0)	80 (24.5)	247 (75.5)	
Moderate Risk	425 (52.0)	137 (32.2)	288 (67.8)	
High Risk	66 (8.1)	33 (50.0)	33 (50.0)	
<i>Other Drug Use, past 3 months^a</i>				$\chi^2(1)=4.20, p=0.041$

	STI Diagnosis^c			Test Statistic
	Total N=823	Yes (n=251, 30.5%)	No (n=572, 69.5%)	
	N (%)	N (%)	N (%)	
Yes	192 (23.3)	70 (36.5)	122 (63.5)	
No	631 (76.7)	181 (28.7)	450 (71.3)	
Other Drug High Risk Score^b				<i>p</i> =0.205
Low Risk	760 (92.3)	226 (29.7)	534 (70.3)	
Moderate Risk	15 (1.8)	7 (46.7)	8 (53.3)	
High Risk	48 (5.8)	18 (37.5)	30 (62.5)	
	M (SD)	M (SD)	M (SD)	
Age	21.48 (2.01)	21.26 (2.04)	21.58 (1.99)	t(821)=-2.11, <i>p</i> =0.036

Note:

^aOther Drug Use= Any report of monthly or greater cocaine, inhalants, sedatives, hallucinogens, opioids, or methamphetamine

^bOther Drug High Risk Score= Composite of Any Other Drug Moderate Risk (11–26) or High Risk (27 or greater).

^cThe second and third columns present the % of each group (STI yes vs. no) that had a given characteristic.

Table 2

Generalized Estimating Equation (GEE) Model Predicting STI Diagnosis

	AOR (95% CI)
<i>Age</i>	1.15 (0.99, 1.32)
<i>Gender Identity (Referent Female)</i>	
Male	6.50 (2.97, 14.22) ***
Transgender	1.61 (0.36, 7.24)
<i>Ever Incarcerated (Referent Never Incarcerated)</i>	0.67 (0.35, 1.28)
<i>Weekly or Greater Alcohol Use^a</i>	0.94 (0.47, 1.88)
<i>Weekly or Greater Marijuana Use^a</i>	10.66 (4.39, 25.87) ***
<i>Monthly or Greater Other Drug Use^b</i>	0.79 (0.39, 1.62)
<i>Alcohol Risk Score (Referent Low Risk)</i>	
Moderate	5.23 (2.50, 10.93) ***
High	6.53 (1.20, 35.68) *
<i>Marijuana Risk Score (Referent Low Risk)</i>	
Moderate	0.50 (0.21, 1.17)
High	2.41 (0.48, 12.12)

Note: GEE Model adjusts for sites.

^a Alcohol and Marijuana Use is reporting weekly or daily/almost daily use compared to monthly or no use.

^b Other Drug Use is reporting at least monthly or more use of cocaine, inhalants, sedatives, hallucinogens, opioids, or methamphetamine compared to no use. Other Drug Risk Scores were not included given the small number of participants who reported any use and risk was not associated with STIs in bivariate analyses.

AOR=Adjusted Odds Ratio. 95%CI= 95% Confidence Interval.

***
p<0.001;

**
p<0.01;

*
p<.05